Beyond Achondroplasia has nearly 2 million views from 207 countries. It was started as a blog in April 2013 and it was done by me only, after work and weekends, until 2017. And since then, fantastic people started to support by volunteering and made it possible the creation of this multilingual platform.

Pfizer announced on the 9th May 2019 that it has entered into a definitive agreement to acquire all the shares of Therachon Holding AG, a clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia and short bowel syndrome (SBS).

One of most relevant events on achondroplasia was held by ALPE Foundation (based in Spain), on the 12,13 and 14th October 2018, bringing together leading healthcare experts in dysplasias, pharmaceutical companies, patient organizations, and more than 500 participants.

Beyond Achondroplasia is now converted into a multilanguage platform, with a new image and structure. We are launching it in English, Spanish, Portuguese and Russian. It will now be easier to find the information you need about achondroplasia.

EURORDIS is calling for patient organizations to join the European Patient Advocacy Groups. Learn more about them and how to apply here.

There are several funds and foundations that fund projects for children with rare diseases. Here is a list of some of them, as well as what their aims are and their deadlines.